These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 11811378)

  • 1. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?
    Rossi GP
    Curr Hypertens Rep; 2006 Jun; 8(3):262-8. PubMed ID: 17147926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase-dependent signaling pathways.
    Rossi GP; Andreis PG; Neri G; Tortorella C; Pelizzo MR; Sacchetto A; Nussdorfer GG
    J Investig Med; 2000 Sep; 48(5):343-50. PubMed ID: 10979239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
    Pitt B
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):145-9. PubMed ID: 7786835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone in congestive heart failure.
    Soberman JE; Weber KT
    Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
    Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
    Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
    Zannad F; Radauceanu A
    Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
    Lijnen PJ; Petrov VV
    Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system.
    Rossi GP; Sacchetto A; Cesari M; Pessina AC
    Cardiovasc Res; 1999 Aug; 43(2):300-7. PubMed ID: 10536660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system.
    Yamamoto K; Masuyama T; Sakata Y; Doi R; Ono K; Mano T; Kondo H; Kuzuya T; Miwa T; Hori M
    Cardiovasc Res; 2000 Jun; 46(3):421-32. PubMed ID: 10912453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
    Zannad F; Dousset B; Alla F
    Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.